Get the Stockscreener App
9.90
9.26%
-1.01
After Hours:
9.54
-0.36
-3.64%
Eikon Therapeutics Inc stock is traded at $9.90, with a volume of 402.31K.
It is down -9.26% in the last 24 hours and up +2.54% over the past month.
Eikon Therapeutics Inc is a late-stage clinical biopharmaceutical company dedicated to building a world-wide , fully-integrated organization developing important, medicines to address serious unmet medical needs. It operates in a single operating segment, which is in the business of drug discovery leveraging its proprietary technology and clinical development of its product candidates. Its product candidates include: EIK1001, EIK1003, EIK1004, EIK1005, and EIK1006.
See More
Previous Close:
$10.91
Open:
$11
24h Volume:
402.31K
Relative Volume:
1.17
Market Cap:
$535.97M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-6.95%
1M Performance:
+2.54%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$9.82
$11.37
1-Week Range:
$9.82
$11.50
52-Week Range:
$7.90
$16.50
Eikon Therapeutics Inc Stock (EIKN) Company Profile
Name
Eikon Therapeutics Inc
Sector
Industry
Phone
341-777-0566
Address
230 HARRIET TUBMAN WAY, MILLBRAE
Compare EIKN vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EIKN
Eikon Therapeutics Inc
|
9.90 | 590.65M | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Eikon Therapeutics Inc Stock (EIKN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-02-26 | Initiated | BofA Securities | Buy |
| Mar-02-26 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-02-26 | Initiated | JP Morgan | Overweight |
| Mar-02-26 | Initiated | Mizuho | Outperform |
| Mar-02-26 | Initiated | Morgan Stanley | Overweight |
| Feb-26-26 | Initiated | Wedbush | Underperform |
View All
Eikon Therapeutics Inc Stock (EIKN) Latest News
Eikon to present clinical data on three cancer programs at ASCO - Investing.com UK
Eikon Therapeutics to present six abstracts on cancer drug trials at 2026 ASCO meeting - Pluang
Eikon Therapeutics Announces Presentation of Advanced Clinical Data at 2026 ASCO Annual Meeting - Quiver Quantitative
Eikon Therapeutics Announces Availability of Six Abstracts - GlobeNewswire
EIKN SEC FilingsEikon Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
IPO Tracker 2026: Parabilis follows hefty Regeneron deal with IPO push - BioSpace
Number of shareholders of Eikon Therapeutics, Inc. – NASDAQ:EIKN - TradingView
Innovation Endeavors reports 3.37M shares in Eikon Therapeutics (EIKN) - Stock Titan
BofA Securities Maintains Eikon Therapeutics(EIKN.US) With Buy Rating, Maintains Target Price $34 - Moomoo
EIKN Should I Buy - Intellectia AI
Roger Perlmutter holds 2.89M shares of Eikon Therapeutics (NASDAQ: EIKN) - Stock Titan
Eikon Therapeutics, Inc.Common Stock (Nasdaq:EIKN) Stock Quote - FinancialContent
Wedbush Maintains Eikon Therapeutics(EIKN.US) With Sell Rating, Cuts Target Price to $5 - Moomoo
Wedbush Cuts Price Target on Eikon Therapeutics to $5 From $7, Keeps Underperform Rating - marketscreener.com
Eikon Therapeutics Reports First Quarter 2026 Financial Results and Provides Clinical Updates - Sahm
Zebra Technologies, Vishay Precision Group, Quantum Computing, Aramark And Other Big Stocks Moving Higher On Tuesday - Sahm
Eikon Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
IPO cash lifts Eikon Therapeutics (NASDAQ: EIKN) to $596M - Stock Titan
Eikon Therapeutics (Nasdaq: EIKN) details Q1 loss and ASCO 2026 data plans - Stock Titan
Press Release: Eikon Therapeutics Reports First Quarter 2026 Financial Results and Provides Clinical Updates - Moomoo
FMR LLC holds 3.84M EIKON Therapeutics shares (NASDAQ: EIKN) - Stock Titan
Eikon Therapeutics prices upsized IPO at $18 per share By Investing.com - Investing.com Nigeria
[SCHEDULE 13G] Eikon Therapeutics, Inc. Passive Investment Disclosure (>5%) - Stock Titan
Domino's Posts Downbeat Q1 Results, Joins Real Brokerage And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Sahm
Merck reportedly eyeing $30M stake in Eikon Therapeutics’ IPO - MSN
Merck veteran-led Eikon seeks $908M valuation in US IPO - MSN
Should I be cautious with Eikon Therapeutics (EIKN) stock today (Market Focus) 2026-04-20Most Discussed Stocks - Xã Châu Thành
ETFs Investing in Eikon Therapeutics, Inc. Stocks - TradingView
EIKN: Eikon Therapeutics, Inc.Comparison to Industry - Zacks Investment Research
All News for EIKN : Eikon Therapeutics, Inc. - Zacks Investment Research
EIKN : Eikon Therapeutics, Inc. Key Company Metrics & Non-finance Metrics - Zacks Investment Research
Eikon Therapeutics, Inc. News — NASDAQ:EIKN - TradingView
EIKN Forecast — Price Target — Prediction for 2027 - TradingView
Diluted shares outstanding of Eikon Therapeutics, Inc. – BX:EIKN - TradingView — Track All Markets
Number of employees of Eikon Therapeutics, Inc. – NASDAQ:EIKN - TradingView
Eikon Therapeutics, Inc. Statistics – BX:EIKN - TradingView — Track All Markets
EIKN Price Today: Eikon Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC
IPO market strengthens in Q1 2026 as biopharma financings reach $22.82B - BioWorld News
Should I buy Eikon Therapeutics, Inc. (EIKN) - Zacks Investment Research
EIKN Analyst Rating Reiterated at Underperform by Wedbush | EIKN Stock News - GuruFocus
Eikon Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Mizuho reiterates Eikon Therapeutics stock rating on pipeline update By Investing.com - Investing.com Canada
Mizuho reiterates Eikon Therapeutics stock rating on pipeline update - Investing.com
IPO Tracker 2026: Biotech Mega-Rounder Kailera Seeks IPO - BioSpace
Eikon Therapeutics Reports 2025 Financial Results, Upsized IPO, and Key Clinical Pipeline Progress - Minichart
Eikon Therapeutics Reports Q4 and Full Year 2025 Results, Provides Clinical Updates - National Today
Eikon Therapeutics Inc Stock (EIKN) Financials Data
There is no financial data for Eikon Therapeutics Inc (EIKN). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):